SUBLINGUAL APOMORPHINE
    21.
    发明公开

    公开(公告)号:EP3434270A1

    公开(公告)日:2019-01-30

    申请号:EP18189805.7

    申请日:2010-06-11

    摘要: The present invention relates to a pharmaceutical composition in unit dosage form formulated for sublingual administration, wherein said unit dosage form has a first portion comprising apomorphine particles comprising an acid addition salt of apomorphine and a second portion comprising a pH neutralizing agent, wherein the unit dosage from comprises a polymer selected from carboxymethylcellulose, cellulose acetate, ethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, nitrocellulose, polyoxyethylene/polyoxypropylene polymers, copolymers or block copolymers, polyvinylpyrrolidone polymers or derivatives, gums and combinations thereof.

    PYRROLIDINE TRIPLE REUPTAKE INHIBITORS
    27.
    发明公开
    PYRROLIDINE TRIPLE REUPTAKE INHIBITORS 审中-公开
    DREIFACH吡咯烷 - 五羟色胺WIEDERAUFNAHME-INHIBITOREN

    公开(公告)号:EP2974724A1

    公开(公告)日:2016-01-20

    申请号:EP15182162.6

    申请日:2010-02-05

    摘要: In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

    摘要翻译: 在各种实施方案中,本发明提供环烷基吡咯烷化合物及其用于治疗和/或预防各种疾病,病症和综合征的方法,包括中枢神经系统(CNS)障碍,例如抑郁症,焦虑症,精神分裂症和睡眠障碍 以及它们的合成方法。 本发明还涉及含有本发明化合物的药物组合物,以及抑制来自突触裂缝的内源性单胺如多巴胺,5-羟色胺和去甲肾上腺素的再摄取的方法以及调节一种或多种单胺转运蛋白的方法。